Duodenal mucosal resurfacing plus liraglutide eliminates need for insulin in type 2 diabetes

Adding liraglutide and lifestyle counseling to duodenal mucosal resurfacing eliminated the need for insulin therapy in most patients with type 2 diabetes through 18 months, according to data from a feasibility study.“[In] this feasibility study, [duodenal mucosal resurfacing (DMR)], combined with [liraglutide] and supported by lifestyle counselling, eliminated the need for insulin therapy in the majority of [type 2 diabetes] patients after 6, 12 and 18 months, while improving their glycemic and metabolic health,” Annieke C.G. van Baar, MD, PhD candidate, from the department ofRead More

Share on facebook
Share on twitter
Share on linkedin